Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer

To evaluate the impact of the Laparoscopic Approach to Cervical Cancer (LACC) Trial on patterns of care and surgery-related morbidity in early-stage cervical cancer

COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)

OBJECTIVES: Italy was one of the first countries significantly affected by the coronavirus disease 2019 (COVID-19) epidemic. The Italian Society for Rheumatology promptly launched a retrospective and anonymised data collection to monitor COVID-19 in patients with rheumatic and musculoskeletal diseases (RMDs), the CONTROL-19 surveillance database, which is part of the COVID-19 Global Rheumatology Alliance. METHODS: CONTROL-19 includes patients with RMDs and proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) updated until May 3rd 2020. In this analysis, only molecular diagnoses were included. The data collection covered demographic data, medical history (general and RMD-related), treatments and COVID-19 related features, treatments, and outcome. In this paper, we report the first descriptive data from the CONTROL-19 registry. RESULTS: The population of the first 232 patients (36% males) consisted mainly of elderly patients (mean age 62.2 years), who used corticosteroids (51.7%), and suffered from multi-morbidity (median comorbidities 2). Rheumatoid arthritis was the most frequent disease (34.1%), followed by spondyloarthritis (26.3%), connective tissue disease (21.1%) and vasculitis (11.2%). Most cases had an active disease (69.4%). Clinical presentation of COVID-19 was typical, with systemic symptoms (fever and asthenia) and respiratory symptoms. The overall outcome was severe, with high frequencies of hospitalisation (69.8%), respiratory support oxygen (55.7%), non-invasive ventilation (20.9%) or mechanical ventilation (7.5%), and 19% of deaths. Male patients typically manifested a worse prognosis. Immunomodulatory treatments were not significantly associated with an increased risk of intensive care unit admission/mechanical ventilation/death. CONCLUSIONS: Although the report mainly includes the most severe cases, its temporal and spatial trend supports the validity of the national surveillance system. More complete data are being acquired in order to both test the hypothesis that RMD patients may have a different outcome from that of the general population and determine the safety of immunomodulatory treatments

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19

Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people

Aims: Antiplatelet therapy is recommended for the secondary prevention of cardio- and cerebrovascular disease, but for primary prevention it is advised only in patients at very high risk. With this background, this study aims to assess the appropriateness of antiplatelet therapy in acutely hospitalized older people according to their risk profile. Methods: Data were obtained from the REPOSI register held in Italian and Spanish internal medicine and geriatric wards in 2012 and 2014. Hospitalized patients aged 6565 assessable at discharge were selected. Appropriateness of the antiplatelet therapy was evaluated according to their primary or secondary cardiovascular prevention profiles. Results: Of 2535 enrolled patients, 2199 were assessable at discharge. Overall 959 (43.6%, 95% CI 41.5\u201345.7) were prescribed an antiplatelet drug, aspirin being the most frequently chosen. Among patients prescribed for primary prevention, just over half were inappropriately prescribed (52.1%), being mainly overprescribed (155/209 patients, 74.2%). On the other hand, there was also a high rate of inappropriate underprescription in the context of secondary prevention (222/726 patients, 30.6%, 95% CI 27.3\u201334.0%). Conclusions: This study carried out in acutely hospitalized older people shows a high degree of inappropriate prescription among patients prescribed with antiplatelets for primary prevention, mainly due to overprescription. Further, a large proportion of patients who had had overt cardio- or cerebrovascular disease were underprescribed, in spite of the established benefits of antiplatelet drugs in the context of secondary prevention

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and e13a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients ≥ 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associated with gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients ≥ 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission

Precision measurement of the ratio of the Lambda(0)(b) to (B)over-bar(0) lifetimes

The LHCb measurement of the lifetime ratio of the Lambda(0)(b) baryon to the (B) over bar (0) meson is updated using data corresponding to an integrated luminosity of 3.0 fb(-1) collected using 7 and 8 TeV centre-of-mass energy pp collisions at the LHC. The decay modes used are Lambda(0)(b) -> J/psi pK(-) and (B) over bar (0) -> J/psi pi K-+(-), where the pi K-+(-) mass is consistent with that of the (K) over bar*(0)(892) meson. The lifetime ratio is determined with unprecedented precision to be 0.974 +/- 0.006 +/- 0.004, where the first uncertainty is statistical and the second systematic. This result is in agreement with original theoretical predictions based on the heavy quark expansion. Using the current world average of the (B) over bar (0) lifetime, the Lambda(0)(b) lifetime is found to be 1.479 +/- 0.009 +/- 0.010 ps. (C) 2014 The Authors. Published by Elsevier B.V

Identification of beauty and charm quark jets at LHCb

Identification of jets originating from beauty and charm quarks is important for measuring Standard Model processes and for searching for new physics. The performance of algorithms developed to select b- and c-quark jets is measured using data recorded by LHCb from proton-proton collisions at root s = 7TeV in 2011 and at root s = 8TeV in 2012. The efficiency for identifying a b (c) jet is about 65%(25%) with a probability for misidentifying a light-parton jet of 0.3% for jets with transverse momentum pT > 20GeV and pseudorapidity 2 : 2 < eta < 4.2. The dependence of the performance on the pT and eta of the jet is also measured

Observation of the decay (B)over-bar(s)(0) -> psi(2S)K+pi(-)

The decay (B) over bar (0)(s) -> psi(2S)K+pi(-) is observed using a data set corresponding to an integrated luminosity of 3.0 fb(-1) collected by the LHCb experiment in pp collisions at centre-of-mass energies of 7 and 8 TeV. The branching fraction relative to the B-0 -> psi(2S)K+pi(-) decay mode is measured to be B((B) over bar (0)(s) -> psi(2S)K+pi(-))/B(B-0 -> psi(2S)K+pi(-)) = 5.38 +/- 0.36 (stat) +/- 0.22 (syst) +/- 0.31 (f(s)/f(d)) %, where f(s)/f(d) indicates the uncertainty due to the ratio of probabilities for a b quark to hadronise into a B-s(0) or B-0 meson. Using an amplitude analysis, the fraction of decays proceeding via an intermediate K*(892)(0) meson is measured to be 0.645 +/- 0.049 (stat) +/- 0.049 (syst) and its longitudinal polarisation fraction is 0.524 +/- 0.056 (stat) +/- 0.029 (syst). The relative branching fraction for this component is determined to be B((B) over bar (0)(s) -> psi(2S)K*(892)(0))/B(B-0 -> psi(2S)K*(892)(0)) = 5.58 +/- 0.57 (stat) +/- 0.40 (syst) +/- 0.32 (f(s)/f(d)) %. In addition, the mass splitting between the B-s(0) and B-0 mesons is measured as M(B-s(0)) - M(B-0) = 87.45 +/- 0.44 (stat) +/- 0.09 (syst) MeV/c(2). (C) 2015 CERN for the benefit of the LHCb Collaboration. Published by Elsevier B.V. This is an open access article under the CC BY licens

Observation of the B0→ρ0ρ0 decay from an amplitude analysis of B0→(π+π−)(π+π−) decays

Proton-proton collision data recorded in 2011 and 2012 by the LHCb experiment, corresponding to an integrated luminosity of 3.0 fb(-1), are analysed to search for the charmless B-0 -> rho(0)rho(0) decay. More than 600 B-0 -> (pi(+)pi(-))(pi(+)pi(-)) signal decays are selected and used to perform an amplitude, analysis, under the assumption of no CP violation in the decay, from which the B-0 -> rho(0)rho(0) decay is observed for the first time with 7.1 standard deviations significance. The fraction of B-0 -> rho(0)rho(0) decays yielding a longitudinally polarised final state is measured to be f(L) = 0.745(-0.058)(+0.048)(stat) +/- 0.034(syst). The B-0 -> rho(0)rho(0) branching fraction, using the B-0 -> phi K*(892)(0) decay as reference, is also reported as B(B-0 -> rho(0)rho(0)) = (0.94 +/- 0.17(stat) +/- 0.09(syst) +/- 0.06(BF)) x 10(-6). (C) 2015 CERN for the benefit of the LHCb Collaboration. Published by Elsevier B.V. This is an open access article under the CC BY licens